This asx biotech company has piled on more than 25% after a big announcement

MotleyFool

Mar 16

Shares in Tetratherix Ltd (ASX: TTX) have surged more than 25% in early trade after the company announced a deal which could earn it more than US$30 million over the next 10 years. The drug ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2619448712"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619448712\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619448712?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619448712","market":"nz","top_or_hot":-1,"title":"This asx biotech company has piled on more than 25% after a big announcement","media":"MotleyFool","content":"<div>\n<p>Shares in Tetratherix Ltd (ASX: TTX) have surged more than 25% in early trade after the company announced a deal which could earn it more than US$30 million over the next 10 years.  The drug ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/16/this-asx-biotech-company-has-piled-on-more-than-25-after-a-big-announcement/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This asx biotech company has piled on more than 25% after a big announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis asx biotech company has piled on more than 25% after a big announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-16 09:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/16/this-asx-biotech-company-has-piled-on-more-than-25-after-a-big-announcement/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares in Tetratherix Ltd (ASX: TTX) have surged more than 25% in early trade after the company announced a deal which could earn it more than US$30 million over the next 10 years.  The drug ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/16/this-asx-biotech-company-has-piled-on-more-than-25-after-a-big-announcement/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.fool.com.au/2026/03/16/this-asx-biotech-company-has-piled-on-more-than-25-after-a-big-announcement/","article_id":"2619448712","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/16/this-asx-biotech-company-has-piled-on-more-than-25-after-a-big-announcement/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619448712","pubTimestamp":1773626081,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Shares in Tetratherix Ltd (ASX: TTX) have surged more than 25% in early trade after the company announced a deal which could earn it more than US$30 million over the next 10 years.  The drug developme","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","TTX.AU":"Tetratherix Ltd"},"translate_title":"这家澳大利亚证券交易所生物技术公司在发布重大公告后股价上涨超过25%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TTX.AU":1},"content_text":"Shares in Tetratherix Ltd (ASX: TTX) have surged more than 25% in early trade after the company announced a deal which could earn it more than US$30 million over the next 10 years.  The drug development company said in a statement to the ASX that it had struck a deal with fellow Australian company Superpower around its \"platform polymer\".  Image source: Getty Images Strong revenue flow Under the deal, Superpower will pay Tetratherix US$3 million per year for up to 10 years and will also purchase Tetratherix's platform polymer branded as STEPP for the nasal delivery of \"longevity and metabolic compounds such as GLP-1, peptides and hormones in the US market''.  Tetratherix said STEPP had been in \"stealth development\" for more than five years and is able to be used for the delivery of a range of compounds. Tetratherix Chief Technology Officer Ali Fathi said:  Our precision medicine franchise is the culmination of more than 5 years of relentless, focused R&D in drug delivery – a journey driven by the conviction that science is only as powerful as its accessibility. I want to thank our research partners who have been instrumental in the development of this once in a generation, enabling technology which will lead to impact beyond our comprehension of what is possible in the way healthcare is delivered. We are now poised to transform the lives of millions across the globe, initially within the high impact landscapes of GLP-1s and peptide therapies with Superpower. Beyond the molecules themselves, this alliance will grant us early, scaled access to real world evidence allowing us to bridge the gap between clinical potential and actual patient outcomes in record time.  Tetratherix said STEPP was a nasal delivery compound that forms a \"sticky cushion\" once inhaled into the nose, and ensures that the drug being delivered remains in place and is not washed away. The company added:  Beyond just staying put on the nasal lining, STEPP acts as a protective bubble wrap for the compounds themselves. Delicate compounds like GLP-1s and peptides are easily broken down by the body's natural enzymes before they can even start working. STEPP wraps these fragile molecules in a defensive layer, shielding them from being destroyed.  Tetratherix Chief Executive Will Knox said the deal was a \"masterstroke in speed and strategic alignment and we couldn't be more excited about working with Superpower''. Shares in the ASX biotech were 27.6% higher at midday at $5.31. The company was valued at $113 million at the close of trade on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}